At the 12th C1-Inhibitor Deficiency & Angioedema Workshop, KalVista Pharmaceuticals, Inc. presents clinical data supporting KVD900 as an oral on-demand treatment for HAE. “Our goal is to provide the best outcome for HAE patients experiencing an attack, and that means offering them the ability to treat early in the attack progression to shorten attack duration,” says Andrew [...]
At the 12th C1 Inhibitor Deficiency and Angioedema Workshop (held virtually 3-6 June 2021), Anne Lesage, Ph.D., Chief Early Development Officer at Pharvaris, presents bradykinin challenge data supporting the pharmacokinetic and pharmacodynamic profile of PHA121 (PHA-022121) for the treatment of HAE. “Findings presented here from pre-clinical and clinical studies, particularly from in vivo bradykinin challenge studies, [...]
Pharming Group N.V. has reached an agreement with the Spanish Ministry of Health to grant reimbursement for Ruconest (conestat alfa) in Spain. Ruconest is the first and only plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy approved for the treatment of acute HAE attacks in adults and children aged 2 years and over. Clinical [...]
Oral, once-daily Orladeyo (berotralstat) from BioCryst Pharmaceuticals, Inc. was approved by the European Medicines Agency (EMA) on 30 April 2021 for the prevention of recurrent HAE attacks in patients 12 years and older - and now the product is available for patients with a prescription in Germany. “We have an experienced team in place in Germany [...]
At the presentation of the Pharvaris financial results for the first quarter ended 31 March 2021, co-founder and CEO Berndt Modig said: “We continue to execute on a development strategy which we believe provides value to shareholders and patients, as demonstrated by the continued enrollment of our Phase 2 on-demand study of PHVS416, from which [...]
Glenmark Pharmaceuticals Limited has received final approval by the United States Food & Drug Administration (U.S. FDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, the generic version of Firazyr Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies, Inc. This marks Glenmark’s first synthetic decapeptide injectable [...]
The pharmacy, distribution and patient management organization Optime Care is pleased to recognize hae day :-) and celebrate the 10th anniversary of an awareness campaign that unites the HAE community. “Access to innovative therapies that can improve quality of life is critical for people with rare diseases like HAE,” says Donovan Quill, President and CEO, Optime [...]
Pharming Group N.V. supports the 10th annual hae day :-), the global awareness day for HAE. CEO Sijmen de Vries comments: “We are proud to support the 10th annual hae day :-) to raise awareness of HAE and better quality of live for patients and their families around the world. Pharming remains dedicated to making a [...]
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for oral, once-daily Orladeyo (berotralstat) for the routine prevention of recurrent HAE attacks in HAE patients 12 years and older. “HAE UK welcomes the decision as HAE is an unpredictable and life-threatening condition which causes significant emotional and economic burdens on people [...]
HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) from CSL Behring - a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prevention of HAE attacks in adolescent and adult patients - is now available in all of Canada. “As a physician that treats this disease, I’m pleased to have HAEGARDA available for patients across Canada. HAEGARDA represents another [...]
